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Peptides derived from the knuckle 
epitope of BMP-9 induce the 
cholinergic differentiation and 
inactivate GSk3beta in human  
SH-SY5Y neuroblastoma cells
Marc-Antoine Lauzon1, Olivier Drevelle1,2 & Nathalie Faucheux1,3
The incidence of brain degenerative disorders like Alzheimer’s disease (AD) will increase as the world 
population ages. While there is presently no known cure for AD and current treatments having only a 
transient effect, an increasing number of publications indicate that growth factors (GF) may be used to 
treat AD. GFs like the bone morphogenetic proteins (BMPs), especially BMP-9, affect many aspects of 
AD. However, BMP-9 is a big protein that cannot readily cross the blood-brain barrier. We have therefore 
studied the effects of two small peptides derived from BMP-9 (pBMP-9 and SpBMP-9). We investigated 
their capacity to differentiate SH-SY5Y human neuroblastoma cells into neurons with or without 
retinoic acid (RA). Both peptides induced Smad 1/5 phosphorylation and their nuclear translocation. 
They increased the number and length of neurites and the expression of neuronal markers MAP-2, 
NeuN and NSE better than did BMP-9. They also promoted differentiation to the cholinergic phenotype 
more actively than BMP-9, SpBMP-9 being the most effective as shown by increases in intracellular 
acetylcholine, ChAT and VAchT. Finally, both peptides activated the PI3K/Akt pathway and inhibited 
GSK3beta, a current AD therapeutic target. BMP-9-derived peptides, especially SpBMP-9, with or 
without RA, are promising molecules that warrant further investigation.
Alzheimer’s disease (AD) is the most common type of dementia, accounting for about 60% of all cases, affecting 
over 40 million people worldwide1. However, there is no cure for AD and the therapies currently available or 
under investigation have only transient effects and slow disease progression2, 3. Most target only one of the three 
major hallmarks of AD at a time (cholinergic system dysfunction4, beta amyloid plaque accumulation5 and Tau 
protein hyperphosphorylation6, 7), although considerable evidence suggests that these hallmarks are all intimately 
linked8–10. Growth factors (GFs) like neurotrophins (nerve growth factor and brain-derived neurotrophic factor), 
bone morphogenetic proteins (BMPs) and insulin-like growth factor 2 (IGF-2), which are found in the develop-
ing and healthy mature brain, but are dysregulated in AD, seem to prevent the evolution of the disease. They could 
act on several AD hallmarks simultaneously and repair the dysfunctional cell signalling8, 11–16.
One subfamily of GFs, the BMPs, may have great potential as they are involved in brain development, main-
tenance and homeostasis8, 17–19. The BMPs, more than 20 at the last count, were discovered in bone tissue by Urist 
and Strates in the early 1970s20–22. BMPs signal in the brain via their type I and type II Serine/Threonine kinase 
receptors and activate the canonical Smad pathway (Smad 1/5/8), which is important in early brain development 
and neuron maturation19, 23, 24.
One BMP, BMP-9, may be a promising candidate for therapy: it is present in the brain and seems to be linked 
to the function of cholinergic neurons25, 26. Lopez-Coviella et al. found high amount of BMP-9 transcripts in 
the spinal cord and septal area of mice11. BMP-9 also activates the transcriptome of basal forebrain cholinergic 
1Department of Chemical and Biotechnological Engineering, Université de Sherbrooke, 2500 boul. de l’Université, 
Sherbrooke, Québec, J1K 2R1, Canada. 2Department of Chemical Engineering, École Polytechnique de Montréal, 
2900, Blvd Édouard Montpetit, Montréal, Québec, H3C 3A7, Canada. 3Clinical Research Center of Centre Hospitalier 
Universitaire de Sherbrooke, 12e Avenue N, Sherbrooke, Québec, J1H 5N4, Canada. Correspondence and requests 
for materials should be addressed to N.F. (email: Nathalie.Faucheux@usherbrooke.ca)
Received: 20 December 2016
Accepted: 22 May 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7: 4695  | DOI:10.1038/s41598-017-04835-x
neurons, which are associated with learning and memory, and is directly implicated in their differentiation25. 
Other evidence indicates that BMP-9 has a direct therapeutic effect on AD hallmarks11–13, 26. Lopez-Coviella 
et al. studied mouse medial septum neurons and showed that BMP-9 increases the expression of cholinergic 
markers in the hippocampus and prevents the loss of choline acetyltransferase (ChAT); this loss is characteristic 
of AD-associated memory loss11. Similarly, Burke et al., working on a mouse model of AD (APP.PS1, transgenic 
mouse overproducing β–amyloid peptides), demonstrated that intraventricular injections of BMP-9 dramatically 
reduced the accumulation of senile plaques in the cortex and hippocampus, and increased the ChAT levels13.
But despite its interesting therapeutic features, recombinant human BMP-9 is expensive to produce and is not 
readily introduced into the brain by systemic or nasal injection because of its size (homodimer of 24 kDa) and 
the great selectivity of the blood brain barrier. Also, BMPs have short half-lives in the circulatory system27. We 
have therefore developed small (23 residues) and relatively inexpensive (300-times less expensive than BMP-9) 
peptides derived from the knuckle epitope of BMP-9. They correspond to the sequence recognized by the BMP 
type II receptor (BMPRII) and are based on the work of Suzuki et al.28 and Saito et al.29 on peptides derived 
from BMP-2. These peptides trigger signalling and cell responses similar to those induced by the whole protein 
(BMP-9) in the context of bone regeneration30–32 but their effects on neurons remain unknown. We therefore 
explored the effects of two BMP-9-derived peptides (pBMP-930 and SpBMP-932) on SH-SY5Y human neuro-
blastoma cells, a well-known human mature neuron cell model that has been used several times in the context of 
AD33–35. Recombinant human BMP-9 was used as a control in all experimental conditions. We also stimulated 
SH-SY5Y cells in the presence of retinoic acid (RA), a potent agent of neuron differentiation36 that is believed to 
be therapeutic for AD37.
Results
pBMP-9 and SpBMP-9 activate the Smad1/5 pathway. Effect of pBMP-9 and SpBMP-9 on kinetic of 
Smad 1/5 phosphorylation. We have recently shown that BMP-9 (1 nM) with or without RA can activate the 
canonical Smad1/5 pathway within 30 min in SH-SY5Y cells8. We therefore verified the ability of both pBMP-9 
and SpBMP-9 (1 nM) to activate the Smad 1/5 pathway (Fig. 1A). The total Smad1/5 (TSmad) was used as a 
control. Without RA, the phosphorylated Smad1/5 (pSmad) bands were detected after incubation for 30 min in 
cells stimulated with pBMP-9 or SpBMP-9. Both peptides in the presence of RA induced the phosphorylation 
of Smad1/5 at 15 min. The Smad1/5 remained phosphorylated within 240 min in the presence of pBMP-9 or 
SpBMP-9 with or without RA. Densitometric analysis of bands corresponding to pSmad1/5 and standardized to 
that of TSmad (Fig. 1A) confirmed that pSmad1/5 levels reached a plateau after 1 h.
Effect of pBMP-9 and SpBMP-9 on the nuclear translocation of phosphorylated Smad1/5. Since pBMP-9 and 
SpBMP-9 induced the phosphorylation of Smad 1/5 (pSmad1/5) in SH-SY5Y cells, we then analyzed the 
Figure 1. Effect of pBMP-9 and SpBMP-9 on the activation of the canonical Smad1/5 pathway. (A) Western 
blots of phosphorylated Smad1/5 (pSmad) and densitometric analysis of pSmad1/5 as referred to total Smad 
(TSmad) showing the effect of 1 nM BMP-9, pBMP-9 and SpBMP-9 +/− 10 μM RA in SH-SY5Y cells after 
incubation for 0, 15, 30, 60, 120 and 240 min. (B) Pictures showing the nucleus (blue) and the pSmad1/5 (red) 
in SH-SY5Y cells stimulated with an equimolar concentration of BMP-9, pBMP-9 or SpBMP-9 (1 nM) +/− 
10 μM RA after incubation for 240 min. Results are representative of 2 independent experiments performed in 
duplicate (Bar = 100 μm).
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pSmad1/5 translocation into the nucleus after incubation for 240 min by labelling both DNA (nucleus) and 
pSmad1/5 (Fig. 1B). Without RA, cells incubated with BMP-9 (1 nM) had a strong pSmad1/5 staining compared 
to untreated cells (CTL) and the pSmad1/5 were mainly located at the nucleus. Both pBMP-9 and SpBMP-9 at 
1 nM induced a slight pSmad1/5 labelling compared to BMP-9. Only some cells possessed a strong nuclear trans-
location of the pSmad1/5. The same tendencies were observed in cells treated by BMP-9 or its derived peptides 
in the presence of RA.
pBMP-9 and SpBMP-9 do not affect the number of SH-SY5Y cells. Effect of pBMP-9 and SpBMP-9 
on cell metabolic activity and viability. We investigated the influence of pBMP-9 and SpBMP-9 with or without 
RA on the viability of SH-SY5Y cells. BMP-9 was used as a control. We measured the activity of the enzyme suc-
cinate dehydrogenase using the MTS assay (Fig. 2A). The control (CTL) showed no alteration in the metabolic 
activity either with or without RA. Incubation for 3d with 0.1 nM BMP-9 or 0.1 nM SpBMP-9 but no RA resulted 
in a significant increase in metabolic activity (p < 0.05) in comparison to the CTL. Similar results were obtained 
after incubation for 5d with 0.1 or 1 nM BMP-9 and with 0.1 nM SpBMP-9. Cells incubated with 0.1 or 1 nM 
BMP-9 and its derived peptides plus RA for 3d and 5d had significantly increased the metabolic activity.
Effect of pBMP-9 and SpBMP-9 on cell number. Cell nucleus was stained with Hoechst 33342 to verify whether 
the observed increase in metabolic activity were caused by increases in cell numbers (Fig. 2B). In the absence of 
RA, there was no significant difference between experimental conditions, neither in function of time. In the pres-
ence of RA, after 5d of incubation, cells stimulated with BMP-9 (1 nM), pBMP-9 (0.1 nM) or SpBMP-9 (0.1 nM) 
had a significant increased amount of nucleus relative fluorescence intensity in comparison with the control, 
those results being in accordance with the metabolic enzymatic assay. There was a determination coefficient of 0.7 
between indirect cell counting and MTS assay results, which indicates that the metabolic activity might be related 
to the number of cells (Fig. 2C).
However, since the cell number was evaluated indirectly by measuring the relative fluorescence intensity of 
the nucleus staining, we then looked at the cell nucleus in a higher magnification to evaluate if the increase in the 
cell number in experiments performed with RA could rather be explained by the presence of pyknotic cell nuclei 
Figure 2. Effect of pBMP-9 and SpBMP-9 on the metabolic enzymatic activity and indirect cell counting. 
(A) MTS assays of SH-SY5Y cells stimulated for 1d, 3d and 5d with equimolar concentrations (0.1 and 1 nM) 
of BMP-9, pBMP-9 and SpBMP-9 +/− 10 μM RA in serum-free culture medium (⬨p < 0.05 and ⬨⬨⬨p < 0.001 
compared with the control without RA, *p < 0.05, **p < 0.01 and ***p < 0.001 compared with the control with 
RA). Results are the means ± SEM of at least two independent experiments performed in duplicate. (B) Indirect 
cell counting showing the relative fluorescence intensity of the stained nuclei in cells used to perform the MTS 
assays (*p < 0.05, ** p < 0.01, ***p < 0.001). (C) Indirect cell counting results plot in function of the MTS 
enzymatic assay results showing a correlation of 0.7. (D) Cell nucleus staining in SH-SY5Y cells stimulated by 
BMP-9, pBMP-9 or SpBMP-9 (0.1 and 1 nM) in the presence of 10 μM RA for 5d (Bar = 100 μm).
www.nature.com/scientificreports/
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(Fig. 2D). There were some pyknotic nuclei for cells stimulated for 5d in the presence of BMP-9, pBMP-9 and 
SpBMP-9 plus RA. From those results, it appears that cells stimulated with BMP-9, pBMP-9 and SpBMP-9, espe-
cially in the presence of RA increase their metabolic activity, which is not caused by an increase in cell number.
pBMP-9 and SpBMP-9 affect the morphology of SH-SY5Y cells and increase their neurites out-
growth. Effect of pBMP-9 and SpBMP-9 on cell morphology. The impact of BMP-9, pBMP-9 and SpBMP-9 
on neuron well-being and the differentiation of cells like SH-SY5Y require an examination of the cell morphology 
(Fig. 3A). Cells incubated in serum free-medium with BMP-9, especially at 1 nM, reacted more like neuroblas-
toma cancerous cells, forming clusters with less neuron-like morphology. Cells stimulated with pBMP-9 and 
SpBMP-9 show an increase amount of neurite outgrowth. RA had a dramatic effect on cell morphology under all 
experimental conditions: it increased neurite outgrowth and displayed more neuronal morphology. Cells stimu-
lated with pBMP-9 or pBMP-9 plus RA had more interconnected neurites than did control plus RA.
We then measured the average length of neurites under each experimental condition (Fig. 3B). SH-SY5Y cells 
stimulated with pBMP-9 (at least p < 0.01) or SpBMP-9 (p < 0.001) without RA had longer neurites than those 
stimulated with BMP-9 or the CTL. Adding RA increased the neurite length under all experimental conditions. 
Cells stimulated with 0.1 nM BMP-9 or 0.1 and 1 nM pBMP-9 and SpBMP-9 plus RA had significant (p < 0.001) 
longer neurites than the corresponding CTL, whereas the neurites of cells stimulated with 1 nM BMP-9 plus RA 
were not significant different from those of CTL. The lower concentrations (0.1 nM) of both pBMP-9 (p < 0.05) 
and SpBMP-9 (p < 0.01) stimulated the formation of significantly longer neurites than did the higher concentra-
tion (1 nM).
pBMP-9 and SpBMP-9 increase the expression of early and late neuronal differentiation mark-
ers. Effect of stimulation time on neuron markers expression. Since pBMP-9 and SpBMP-9 had an effect on 
the morphology of SH-SY5Y cells inducing neurite formation characteristic of the neuron phenotype, we used 
Western blots to evaluate the expression of MAP-2 protein, an early marker of neuron differentiation38 (Fig. 4A). 
There was significantly more of MAP-2 in cells stimulated with pBMP-9 and SpBMP-9 (0.1 nM) without RA for 
5d than in the CTL as shown by the densitometric analyses (p < 0.05). There was a significant increase in MAP-2 
in cells stimulated for 3d with pBMP-9 or SpBMP-9 plus RA in comparison to BMP-9 plus RA (p < 0.01). Finally, 
the expression of MAP-2 decreased between 3d and 5d in the CTL (p < 0.05) and in cells treated with SpBMP-9 
(p < 0.05), while it increased in cells stimulated with BMP-9 (p < 0.05). The MAP-2 levels in cells stimulated with 
pBMP-9 for 3d and 5d were the same.
Neuron markers distribution. Knowledge of the distribution of neuron differentiation markers in cells is essen-
tial for confirming the neuron phenotype. For example, NeuN is specific to neuron cells and is restricted to the 
cell nucleus39, 40. We used immunolabelling to determine the effect of BMP-9, pBMP-9 and SpBMP-9 on the 
Figure 3. Effect of pBMP-9 and SpBMP-9 on the morphology of SH-SY5Y cells and neurite length. (A) 
Modified phase-contrast pictures of SH-SY5Y cells stimulated for 5d with equimolar concentrations (0, 0.1 and 
1 nM) of BMP-9, pBMP-9 and SpBMP-9 +/− 10 μM RA. Pictures are representative of at least 3 independent 
experiments performed in duplicate. Neurites and cell bodies were highlighted with an edge-detection filter and 
superimposed (blue edges) on the original phase contrast image (Bar = 100 μm). (B) Average neurite length of 
SH-SY5Y cells stimulated for 5d with equimolar concentration of BMP-9, pBMP-9 or SpBMP-9 (0.1 and 1 nM) 
+/− 10 μM RA determined as the Euclidean distance between the end of neurites and the cell body. Results 
are the means ± SEM of at least 3 independent experiments performed in duplicate, where a total of over 300 
measurements were taken per experimental condition (*p < 0.05, **p < 0.01, ***p < 0.001).
www.nature.com/scientificreports/
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expression and distributions of the markers of early (βIII-tubulin, MAP-2) and late neuron differentiation (NeuN 
and NSE) in cells incubated for 5d (Fig. 4B).
We detected βIII-tubulin under all experimental conditions, but it was most prominent in cells stimulated 
with RA for all experimental conditions. BMP-9 without RA produced less intense labelling regardless of its con-
centration. However the cells stimulated with pBMP-9 or SpBMP-9 contained more markers than did the control 
or those stimulated with BMP-9 with or without RA.
MAP-2 was most abundant in the neurites of SH-SY5Y cells stimulated with 0.1 or 1 nM pBMP-9 or SpBMP-9, 
especially in the presence of RA. Since MAP-2 is a microtubule-associated protein, an increase in its expression 
and its distribution in the neurites is associated with greater neuronal differentiation38. Staining for the marker 
of late differentiation, NeuN, in cell nuclei39, was more intense in cells stimulated with pBMP-9, and especially 
SpBMP-9, with or without RA, than in cells stimulated with BMP-9 or the CTL (Fig. 4B). SH-SY5Y cells stimu-
lated with 1 nM BMP-9 were poorly stained, especially those incubated without RA. However, there was some 
staining in the cell body around the nucleus. This could be due to the presence of synapsin I, which is recognized 
by NeuN antibodies41. Finally, incubation with pBMP-9 or SpBMP-9 produced the best staining for NSE, a late 
marker located in the cell cytoplasm, regardless of their concentration or the presence of RA.
These results indicate that pBMP-9 and SpBMP-9 induce more rapid neuron differentiation than the whole 
BMP-9 protein or the CTL, especially in the presence of RA. However, greater neuron differentiation does not 
necessarily mean that cells are moving toward the cholinergic phenotype.
SpBMP-9 increases the expression of choline acetyltransferase, vesicular acetylcholine trans-
porter protein and the level of intracellular acetylcholine. BMP-9 activates the cholinergic tran-
scriptome of murine septal cells and basal forebrain cholinergic neurons and increase the levels of Ach and the 
vesicular acetylcholine transporter protein (VAchT)11, 25, 26. Ach is synthesized in the cell body by fusion of acetyl 
Co-A and choline catalysed by choline acetyltransferase (ChAT); it is then transported to vesicles by VAchT. The 
ChAT and VAchT genes are conserved at the same locus, which suggests that their expressions are coordinated42. 
Figure 4. Effect of pBMP-9 and SpBMP-9 on the differentiation of SH-SY5Y cells. (A) Western blots of MAP-2 
and βactin (2 independent experiments) and densitometric analyses of MAP-2 bands normalized to βactin 
(means ± SEM) for SH-SY5Y cells stimulated with 0.1 nM BMP-9, pBMP-9 and SpBMP-9 +/− 10 μM RA for 
3d and 5d (*p < 0.05, **p < 0.01). Only cropped pictures of western blots showing the 80 kDa MAP-2 isoform 
were presented in order to allow a better comparison between experimental conditions. Complete gel pictures 
are available in the supplementary data file. (B) Merged pictures showing immunostaining for neuronal 
differentiation markers βIII-tubulin (Alexa Fluor® 488, green), MAP-2 (Alexa Fluor® 488, green), NeuN 
(FITC, green) and NSE (FITC, green), and nuclei staining (Hoechst, blue) of SH-SY5Y cells stimulated for 5d 
with 0, 0.1 or 1 nM BMP-9, pBMP-9 and SpBMP-9 +/− 10 μM RA. Pictures are representative of at least two 
independent experiments (Bar = 100 μm).
www.nature.com/scientificreports/
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We investigated the effect of pBMP-9 and SpBMP-9 on the induction and the maintenance of the cholinergic 
phenotype since cholinergic dysfunction is a major hallmark of AD (Figs 5–7).
Effect of pBMP-9 and SpBMP-9 on choline acetyltransferase. The ChAT enzyme responsible for converting 
acetyl-co-A and choline to acetylcholine in SH-SY5Y cells incubated with BMP-9 or its derived peptides with 
or without RA was detected by immunolabelling (Fig. 5A and B). We found ChAT immunostaining in all cell 
bodies under all experimental conditions (Fig. 5A). However, the intensity of labelling differed, especially when 
the cells were stimulated with SpBMP-9 without RA. The CTL without RA had the lowest ChAT staining, while 
cells incubated with 0.1 nM SpBMP-9 had the highest ones as confirmed by the relative fluorescence intensity 
Figure 5. Effect of pBMP-9 and SpBMP-9 on the expression of choline acetyltransferase. (A) Merged pictures 
showing immunostaining for ChAT (FITC, green) and nuclei labelling (Hoechst, blue) of SH-SY5Y cells 
stimulated for 5d with 0, 0.1, or 1 nM BMP-9, pBMP-9 and SpBMP-9 +/− 10 μM RA (Bar = 100 μm). Pictures 
are representative of at least 2 independent experiments. (B) Analysis of ChAT fluorescence intensity relative to 
the nucleus staining was also presented. Results are the means ± SEM (***p < 0.001).
Figure 6. Effect of pBMP-9 and SpBMP-9 on the expression and the distribution of VAchT. Merged pictures 
showing immunostaining for VAchT (FITC, green), actin cytoskeleton (rhodamine-phalloidin, red) and nuclei 
labelling (Hoechst, blue) of SH-SY5Y cells stimulated for 5d with 0, 0.1 or 1 nM BMP-9, pBMP-9 and SpBMP-9 
+/− 10 μM RA. White squares show magnified zones, white arrows indicate VAchT vesicles in cell neurites 
(Bar = 100 μm). Pictures are representative of at least 2 independent experiments.
www.nature.com/scientificreports/
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analysis (p < 0.05) (Fig. 5B). Cells stimulated with BMP-9 and pBMP-9 had similar fluorescence intensities as the 
control, which were lower than that of SpBMP-9-stimulated cells. However, no difference in relative fluorescence 
intensities was observed when the same assays were run in the presence of RA.
Effect of incubation time and pBMP-9 or SpBMP-9 dose on intracellular acetylcholine concentration and VAchT 
expression and distributions within cells. VAchT in the axon terminals plays an important role in the accumula-
tion of Ach prior to its release43. We immunolabelled VAchT to evaluate the effects of SpBMP-9 and pBMP-9 on 
its expression and distribution in the cells (5d, Fig. 6). The presence of labelled VAchT in small vesicles within the 
neurites indicates a cholinergic differentiation. Only cells stimulated with 0.1 nM or 1 nM SpBMP-9 (without RA) 
had VAchT vesicles in their neurites, with 1 nM being more efficient. RA alone significantly stimulated VAchT 
accumulation in the neurites. Cells stimulated with 0.1 nM BMP-9, 0.1 and 1 nM pBMP-9 and SpBMP-9 plus RA 
all had similar amounts and distributions of VAchT vesicles in the neurites. However, cells stimulated with 1 nM 
BMP-9 contained no vesicles.
We then measured intracellular Ach to determine the abilities of BMP-9 and its derived peptides to stim-
ulate the synthesis of Ach in SH-SY5Y cells (Fig. 7A). Only 1 nM SpBMP-9 (p < 0.01) and pBMP-9 (p < 0.05) 
significantly stimulated Ach synthesis after incubation for 3d without RA. The concentration of Ach in SH-SY5Y 
cells stimulated with 1 nM SpBMP-9 for 5d was also higher than that in unstimulated cells (p < 0.05) or cells 
stimulated with 0.1 nM BMP-9 (p < 0.01). Cells incubated for 3d in the presence of RA plus 1 nM BMP-9, 0.1 or 
1 nM pBMP-9 or SpBMP-9 contained more Ach than did the CTL, while those incubated with SpBMP-9 had the 
highest Ach concentration (p < 0.001). For the SH-SY5Y cells stimulated with BMP-9, pBMP-9 or SpBMP-9 for 
5d in the presence of RA, intracellular Ach levels, except for cells stimulated with 1 nM of BMP-9, were similar to 
the CTL plus RA.
Effect of pBMP-9 and SpBMP-9 on acetylcholinesterase activity. We measured AchE activity to determine the 
action of SpBMP-9 on Ach breakdown (Fig. 7B). AchE cleaves the neurotransmitter released into the synaptic clef 
to give choline and acetic acid; the choline is then recycled back into the cells. Only the SH-SY5Y cells incubated 
for 5d with SpBMP-9, but no RA, contained AchE activity that was significantly enhanced in comparison to the 
CTL (p < 0.05) (Fig. 7B). However, the presence of RA increase significantly in all experimental conditions the 
relative AchE activity compared to the cells without RA (p < 0.001). In addition, cells incubated with BMP-9 or its 
derived peptides plus RA had AchE activities similar to the control plus RA.
pBMP-9 and SpBMP-9 increase the activation PI3K/Akt pathway and inactivate GSK3β. Since 
SpBMP-9 has been shown to induce a higher cholinergic differentiation of SH-SY5Y cells, we then evaluated the 
effect of SpBMP-9 on the activation state of GSK3β, a Tau kinase44. As GSK3β can be inactivated by Akt-catalysed 
phosphorylation of its Ser944, 45, we first analyzed the activation state of Akt in cells incubated with BMP-9, 
pBMP-9 or SpBMP-9 with and without RA.
Phosphorylation of Akt at Thr308. We analyzed the effect of equimolar concentration of BMP-9, pBMP-9 or 
SpBMP-9 (0.1 nM) with or without RA on the phosphorylation of Akt at its catalytic site (Thr308) by immunos-
taining (Fig. 8A). Cells stimulated with pBMP-9 or SpBMP-9 showed a higher level of fluorescence corresponding 
to pAkt (Thr308) compared to unstimulated cells or those incubated with BMP-9, as confirmed by relative fluo-
rescence intensity analyses of these immunolabellings (p < 0.001). SpBMP-9 was also most effective than pBMP-9 
Figure 7. Effect of pBMP-9 and SpBMP-9 on the intracellular Ach and AchE. (A) Intracellular Ach in SH-SY5Y 
cells stimulated with 0, 0.1 or 1 nM BMP-9, pBMP-9 and SpBMP-9 +/− 10 μM RA for 3d and 5d (B) AchE 
activity for SH-SY5Y cells stimulated with 0, 0.1 or 1 nM BMP-9, pBMP-9 and SpBMP-9 +/− 10 μM RA for 5d. 
Results are the means ± SEM of at least 4 independent experiments (*p < 0.05, **p < 0.01, ***p < 0.001).
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(p < 0.01). In the presence of RA, Akt was phosphorylated at Thr308 in all experimental conditions. BMP-9 or 
pBMP-9 plus RA induced slightly less pAkt on Thr308 in comparison to RA alone (p < 0.001).
Inactivation of GSK3β by its phosphorylation at Ser9. We used Western blotting to assess phosphorylated GSK3β 
(pGSK3β) on Ser9 to determine whether Akt activation leads to inactivation of GSK3β (Fig. 8B). BMP-9, without 
RA, had a transient effect as confirmed by densitometric analysis of bands corresponding to pGSK3β and stand-
ardized to that of β actin: pGSK3β (Ser9) increased between 0 and 60 min, plateaued and then decreased from 
120 to 240 min. Incubation with pBMP-9 and SpBMP-9 gave a different activation pattern. The pGSK3β (Ser9) 
in cells incubated with either pBMP-9 or SpBMP-9 increased from 0 to 240 min. Cells incubated with pBMP-9 
or SpBMP-9 plus RA had similar time-dependent increases in pGSK3β (Ser9). pGSK3β (Ser9) was detected after 
240 min in cells incubated with BMP-9, pBMP-9 or SpBMP-9 plus RA. We confirmed these observations by 
immunostaining for pGSK3β (Ser9) at 4 h (Fig. 8C). pBMP-9 and SpBMP-9 induced a higher level of pGSK3β 
(Ser9) than BMP-9 or the CTL, as confirmed by relative fluorescence intensity analysis (p < 0.001 and p < 0.01 
respectively). In addition, cells incubated with RA alone or combined with BMP-9 or its derived peptides con-
tained more phosphorylated GSK3β on Ser9 than did cells stimulated without RA (p < 0.001).
Discussion
The search for an effective treatment for AD has been, and continues to be, intense. The disease has three main 
hallmarks: cholinergic system dysfunction4, beta amyloid plaque accumulation5 and protein Tau hyperphospho-
rylation6, 7. Several studies have indicated that GFs may be potent therapeutic agents, particularly those of the 
Figure 8. Effect of pBMP-9 and SpBMP-9 on the PI3K/Akt/GSK3β pathway. (A) Merged pictures 
representative of at least 2 independent experiments showing immunostaining for pAkt (Thr308) (green) and 
nuclei (Hoechst, blue) of SH-SY5Y cells stimulated for 2 h with 0.1 nM BMP-9, pBMP-9 and SpBMP-9 +/− 
10 μM RA (Bar = 100 μm) and pAkt(Thr308) fluorescence activity relative to the nucleus. (B) Western blots of 
phosphorylated GSK3β at Ser9 (pGSK3β) and densitometric analysis of pGSK3β bands standardized by actin 
showing the effect of 0.1 nM BMP-9, pBMP-9 and SpBMP-9 +/− 10 μM RA in SH-SY5Y cells after incubation 
for 0, 15, 30, 60, 120 and 240 min. Only cropped pictures of western blots were shown in order to allow a better 
comparison between experimental conditions. Complete gel pictures are available in the supplementary data 
file. (C) Merged pictures representative of at least 2 independent experiments showing immunostaining for 
pGSK3β (Ser9) (FITC, green) and nuclei (Hoechst, blue) in SH-SY5Y cells stimulated for 4 h with 0.1 nM BMP-
9, pBMP-9 and SpBMP-9 +/− 10 μM RA (Bar = 100 μm). Analysis of pGSK3β(Ser9) fluorescence intensity 
relative to the nucleus staining was also presented. Results are the means ± SEM (**p < 0.01, ***p < 0.001).
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TGF-β family, as they act on more than one hallmark simultaneously (8–14). A recent study showed that the 
plasma of 99 AD patients had a deficient TGFβ/GDF/BMP transcriptome, proteasome and signalling. This study 
also indicated that the TGFβ member, growth differentiation factor 3 (GDF3), could be a potent therapeutic agent 
against AD since it plays a role in adult neurogenesis46. BMPs are also part of the TGFβ family. They influence 
brain development and neurogenesis8, 17–19 and so could have a great impact on brain degenerative diseases, par-
ticularly AD. A recent study found that BMP-4 expression increases in mice dentate gyrus as they age, leading 
to an increase of canonical Smad signalling and a decrease in BMP inhibitor Noggin which were associated 
with a decline in cognitive functions47. It was also shown in mice that BMP signalling regulates the depressive 
behavior48. Nonetheless, BMPs are classified into several subfamilies depending on their sequence homologies21. 
Other BMPs such as BMP-9, which are not part of BMP-4 subfamily, have shown promising effect in the context 
of AD11–13. Lopez-Coviella et al. demonstrated that BMP-9 was the most efficient of the BMPs tested (BMP-2, -4, 
-6, -7, -9 and -12) at increasing the acetylcholine in septal neurons as well as their expression of neuron differen-
tiation markers such as βIII-tubulin, ChAT and VAchT11.
However, proteins do not readily cross the blood brain barrier, most are too big. We therefore used two small 
peptides (23 residues) derived from the knuckle epitope of BMP-9, corresponding to the sequence recognized 
by type II BMP receptor (BMPRII), to overcome the size limitation and reduce their cost, since short peptides of 
similar size (980 Da–6.5 kDa) can be delivered intranasally and successfully cross the blood brain barrier49. Our 
peptides sequences were based on the previous work of Saito et al.29, 50 on BMP-2. They showed that peptides 
derived from the knuckle epitope of BMP-2 targeting Type II BMP receptor (BMPRII) could activate the canoni-
cal Smad signalling pathway in the context of bone repair in a similar manner as the whole protein. They have also 
demonstrated that the peptide could interact with both Type I and Type II BMP receptors.
We therefore show that pBMP-9 and SpBMP-9 with or without RA were able to activate the canonical Smad1/5 
pathway in SH-SY5Y cells, a well-used in vitro model to study the effect of drugs against AD33, 34. The SH-SY5Y 
cells expressed both BMPRIb and BMPRII receptors19. The receptor BMPRII is also present in all the brain 
regions associated with memory and task learning (hippocampus and cortex)51. We have already shown in previ-
ous papers that pBMP-9 and SpBMP-9 were also able to activate the canonical Smad signalling pathway in a sim-
ilar way than BMP-9 in murine mesenchymal stem cells C3H10T1/231 and murine preosteoblasts MC3T3-E131, 
32. However, we found that the Smad1/5 activation and their nuclear translocation in SH-SY5Y cells in serum 
free medium appear lower with pBMP-9 or SpBMP-9 compared to BMP-9. Hegarty et al. have shown that the 
Smad pathway activation in SH-SY5Y cells cultured in medium supplemented with 10% (v/v) foetal calf serum is 
required for BMP-2 induced neurite outgrowth19. They also recently found that dynamin dependent endocytosis 
of BMP receptor complexes allows the maximal effect of BMP-2 (200 ng/mL) on neurite outgrowth in SH-SY5Y 
cells cultured in medium containing serum52. We confirmed that pBMP-9 and SpBMP-9 at concentrations in 
the physiological range of BMP-9 (~20 ng/mL) in human53 stimulate the neurite outgrowth in SH-SY5Y cells in 
serum free medium. However, despite a strong Smad1/5 activation and their nuclear translocation, SH-SY5Y cells 
stimulated by BMP-9 in serum-free medium were not able to develop significant neurite outgrowth within 5d in 
comparison to the control. The addition of RA is required to observe some increase in BMP-9 induced neurite 
outgrowth. Furthermore, BMP-9 at 1 nM drastically alters the morphology of SH-SY5Y cells, making them more 
neuroblastoma-like. Further studies are therefore required to better understand by which signalling pathways 
pBMP-9 and SpBMP-9 induced neurite outgrowth in SH-SY5Y cells.
In addition, we verified that both BMP-9 derived peptides did not significantly decrease the cell number 
after incubation for 3d and 5d with or without RA. BMP-9 and its derived peptides with RA had also an effect 
on the metabolic activity of cells, which is unlikely caused by cell proliferation. However, other peptides, such 
as C-peptide54 or other GFs like IGF-1, IGF-255 and NGF56 have also shown to have simultaneous effects on the 
proliferation and neurite outgrowth of SH-SY5Y cells cultivated in serum-free or poor-serum conditions. We 
also found that RA alone had no significant effect on the metabolic activity of the SH-SY5Y cells. Some studies 
observed that RA can stop cell proliferation and promote differentiation in SH-SY5Y cells57–59. In contrast, it was 
also shown that differentiation of SH-SY5Y cells induced by sequential treatment using RA and brain-derived 
neurotrophic factor (BDNF) lead to an increase in ATP level and plasma membrane activity as well as an increase 
in metabolic need60. The impact of the increased metabolism induced by BMP-9 and its derived peptides in the 
presence of RA on subsequent SH-SY5Y cell behavior remains unclear.
We then confirmed that pBMP-9 and SpBMP-9 stimulate more the differentiation markers expression (MAP-
2, NeuN and NSE) than the whole protein BMP-9. We also observed an increase in MAP-2 expression between 
3d and 5d in cells stimulated by BMP-9 alone in serum free medium, despite no significant increase in neurite 
outgrowth at 5d compared to the control. Significant neurite outgrowth in the presence of BMP-9 may take longer 
time to occur and/or other factors may be required to promote neurite outgrowth61–63. Other peptides derived 
from GFs, including neurotrophic factors such as NGF, stimulate neuronal differentiation64, 65. Colangelo et al. 
have shown that 2 small peptides derived from functional sections of NGF can induce neuronal differentiation 
of PC12 cells just like the whole protein64. We also found that RA alone favors neurite outgrowth and increased 
expression of neuronal markers. RA is known to induce SH-SY5Y differentiation36, 66–68. Lopes et al. showed that 
SH-SY5Y cells incubated for 4 and 10d in low (1% v/v) serum medium plus RA contained more terminal dif-
ferentiation proteins like NSE and NeuN than did cells incubated without RA66. RA also enhances the neuronal 
differentiation induced by pBMP-9 and SpBMP-9. The positive effect of RA plus GFs has been observed using 
sequential treatment58, 69. Several studies have shown that SH-SY5Y cells stimulated with RA plus BDNF had 
increased neurite outgrowth and length synergistically and more early and late neuronal differentiation markers 
like MAP-2 and NSE58, 69.
Cholinergic system dysfunction is a major hallmark of AD and BMP-9 is known to promote the cholinergic 
differentiation of neuronal cells11. We have shown that both pBMP-9 and SpBMP-9 enhance the cholinergic phe-
notype of SH-SY5Y cells, with SpBMP-9 being the more efficient. The difference in the effects of SpBMP-9 and 
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pBMP-9 might be due to small differences in their sequences. The two Cysteines in pBMP-9 are replaced by two 
Serines in SpBMP-9, based on the work of Saito et al. on BMP-250. They demonstrated that this small modification 
on BMP-2 derived peptide increased its affinity for type II BMP receptors, so increasing the osteogenic activity50. 
We find that 0.1 nM SpBMP-9 stimulates the synthesis of ChAT, while SpBMP-9 at 1 nM significantly increases 
(60%) intracellular Ach. It also enhances the production of VAchT and its distribution within the cell processes, 
indicating the accumulation of Ach. Adding RA to the culture system also enhances AchE activity and VAchT 
expression in all our experimental conditions. It is already known that RA directs SH-SY5Y cells towards the 
cholinergic phenotype and increases their AchE activity70, 71.
We have also demonstrated that pBMP-9 and SpBMP-9 act on another AD hallmark by preventing the acti-
vation of GSK3β, a Tau kinase. pBMP-9 and SpBMP-9 (0.1 nM) increase the activation of the PI3K/Akt pathway 
at 2 h and inactivate GSK3β in a time dependent manner from time 0 to 4 h. Activation of the PI3K/Akt pathway 
in the central nervous system regulates GSK3β and plays an important role in neuron polarity72. GSK3β is the 
most studied Tau kinase since it can be implicated in Tauopathies such as AD44, 45. Our immunolabelling studies 
indicate that 0.1 nM BMP-9 alone had no effect on PI3K/Akt at 2 h compared to the control, which agrees well 
with its transient effect on GSK3β deactivation via phosphorylation at Ser9. This observation also confirms our 
published results showing that the level of pGSK3β (Ser9) in SH-SY5Y cells incubated with 1 nM BMP-9 alone 
gradually decreases from time 0 to 4 h8. In contrast, BMP-9 (1 nM) plus RA can maintain the phosphorylation of 
GSK3β at Ser9 for over 4 h8. Indeed, the present study also revealed that RA alone or combined with BMP-9 or its 
derived peptides can activate the PI3K/Akt/GSK3β pathway. Cheung et al. found that SH-SY5Y cells incubated 
with RA for 7d contained more phosphorylated Akt than the control36. RA also protects SH-SY5Y cells against 
proteasome inhibition-associated cell death via the PI3K/Akt pathway, which is common in AD57. Since several 
studies have demonstrated that inhibiting GSK3β prevents Tau hyperphosphorylation at many sites33, 73, pBMP-9 
and SpBMP-9, with or without RA, might be effective anti-hyperphosphorylated-Tau agents that could also pro-
tect cells against oxidative stress programmed cell death.
RA and other vitamin A derivatives have already been proposed for AD therapy, as has BMP-9. Our present 
results indicate that two peptides derived from the knuckle epitope of BMP-9, pBMP-9 and SpBMP-9, stimulate 
the differentiation of SH-SY5Y cells in vitro better than the whole protein. SpBMP-9 or pBMP-9 induced terminal 
neuron differentiation, promote cholinergic differentiation and inactivate GSK3β. Thus, BMP-9-derived peptides, 
especially SpBMP-9, alone or combined with RA are worth our attention since they act on several AD hallmarks 
simultaneously. Their small size should make them easier to deliver to the brain tissue. Further in vitro with neu-
ronal stem cells and in vivo studies in appropriate mouse model are needed to confirm the effectiveness of these 
promising peptides.
Materials and Methods
Material. Recombinant carrier-free human BMP-9 was purchased from R&D system Inc. (Minneapolis, MN, 
USA), pBMP-9 and SpBMP-9 were from EZBiolab (Carmel, IN, USA). Retinoic acid (RA) (Sigma Aldrich, ON, 
CA) was dissolved in pure ethanol, and kept frozen in the dark.
Cell culture. SH-SY5Y human neuroblastoma cells (ATCC® CRL-2266TM) were grown on treated polysty-
rene plates in DMEM/F12 (1:1) Glutamax (Gibco®, Grand Island, NY, USA) containing 1% (v/v) streptomy-
cin (100 mg/mL) and penicillin (100 U/mL) plus 10% (v/v) heat-inactivated fetal bovine serum (FBS) (Wisent, 
St-Jerome, QC, CA) at 37 °C under a humidified 5% CO2/air environment. Cells were passaged at 80% confluence 
using trypsin-EDTA (0.25%) (Gibco®, Grand Island, NY, USA). The trypsin was neutralized with 10% (v/v) FBS 
and cells were collected by centrifugation. In all experiments, cells were stimulated in serum-free culture medium 
with or without 10 µM retinoic acid (RA). The ethanol in which the RA was dissolved never exceeded 0.1% (v/v) 
of the medium volume.
Viability assays. SH-SY5Y cells were grown to 80% confluence on 24-well plates, washed with sterile 
phosphate-buffered saline (PBS) and incubated in serum-free culture medium with equimolar concentrations 0, 
0.1 or 1 nM of BMP-9, pBMP-9 or SpBMP-9 with or without 10 µM RA for 1d, 3d and 5d. Viability was assessed 
using MTS CellTiter 96® Aqueous One Solution Cell Proliferation Assay kit following the manufacturer’s instruc-
tion (Promega, Madison, WI, USA). Supernatants were collected after incubation with the MTS reagent and 
absorbance at 490 nm was measured using a Biotek Synergy HT (Biotek® Instruments Inc., Winosski, VT, USA). 
Tests were performed in DMEM without phenol red (Gibco®, Grand Island, NY, USA) to avoid any spectropho-
tometric bias. Results are representative of at least two independent experiments performed in duplicate.
Morphology analysis. SH-SY5Y cells were grown to 80% confluence on 6-well plates, washed with ster-
ile PBS and incubated with equimolar concentrations (0, 0.1 or 1 nM) of BMP-9, pBMP-9 and SpBMP-9 in 
serum-free medium with or without 10 µM RA for 5d. 5–10 representative pictures (magnification: 20X) were 
taken using an Eclipse TE200-S microscope coupled to a CCD camera (Zeiss AxioCam MRm, Car Zeiss, DE). 
Pictures were smoothed with a Gaussian filter to remove noise, with a Laplace high-pass filter and then with 
a median filter to detect and enhance neurites using an image analysis app (MatLab Image Processing Toolbox; 
MatLab 2007b, Mathworks, USA). The resulting images showing the neurite edges (blue lines) were superim-
posed on the original phase-contrast images. Original pictures were shrunk to fit within the figure panel. Each 
experiment was performed at least three times in duplicate.
Measurement of neurite length. Mean neurite lengths were determined from the normal size high res-
olution neurite-enhanced pictures taken for morphology analyses (20x magnification) using an image analysis 
app (Matlab Image Processing Toolbox; MatLab 2007b, Mathworks, USA). Briefly, neurite length was defined as 
the Euclidean distance in pixels or a combination of Euclidean distances between the cell body and the end of a 
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neurite. The longest path was always chosen when a neurite had several branches. The length in pixels was then 
calibrated based on the length bar provided by the microscope image treatment software (AxioVision LE, Carl 
Zeiss, DE). For each experimental condition, 15 to 30 neurites were measured for each picture (4 × 10−3 cm²) 
and at least 5 pictures were analyzed per condition performed. Those steps were done three independent times 
in duplicate. The mean neurite length for each picture analyzed within a replicate was weighted by the number of 
measurement taken. For each independent experiment, the mean was calculated as the weighted mean (relative 
to the inverse of the variance) of each replicate. Finally, the overall mean was calculated as the weighted mean 
(relative to the inverse of the variance) of each of the three independent experiments. Overall, a total of at least 
300 neurite length measurements were obtained for each experimental condition.
Western blotting and densitometric analysis of signalling protein and neuronal differentiation 
marker bands. Cells were grown to 80% confluence in 100 mm diameter tissue culture wells, washed with 
sterile PBS and stimulated with 0.1 nM BMP-9, pBMP-9 or SpBMP-9 in serum-free medium for 3 - 5d for neu-
ronal differentiation markers and between 0 to 240 min for phosphorylated and total Smad 1/5/8 or phosphoryl-
ated GSK3β (Ser9). Treated cells were washed with cold sterile PBS containing 1 mM orthovanadate (Sigma) and 
lysed with 50 mM Tris-HCl (pH 7.4) containing 1 mM orthovanadate (Sigma), 0.1% (v/v) SDS and a complete 
mini-protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN, USA). Equal amounts of protein (15 μg) 
were separated by SDS-PAGE and transferred to polyvinylidene fluoride (PVDF) membranes. Transferred pro-
teins were incubated overnight at 4 °C with primary antibodies against βactin diluted 1:2,000 (Sigma), MAP-2 
diluted 1:1,000 (Cell Signalling, MA, USA), phosphorylated and total Smad diluted 1:1,000 (Cell Signalling, MA, 
USA) or phosphorylated GSK3β (Ser9) diluted 1:1,000 (Cell Signalling, MA, USA). Membranes were washed 
with PBS containing 0.1% (v/v) Tween 20 and incubated with anti-rabbit secondary antibodies (1:10,000) or 
anti-mouse secondary antibodies (1:10,000) coupled to horseradish peroxidase. Immunoreactive bands were vis-
ualized by chemiluminescence (ECL + Plus TM, GE Healthcare, Buckinghamshire, UK) and exposed to X-ray 
films (Thermo scientific, Rockford, Il, USA). Films were then digitalized using a high resolution scanner (Canon 
LidE 120, resolution: 600 × 600 DPI) and the densities of bands determined with an image analysis app (Matlab 
Image Processing Toolbox; MatLab 2007b, Mathworks, USA). Briefly, the intensities of all pixels in a user-defined 
region of interest (ROI) corresponding to a protein band were summed. The average background, the pixel inten-
sities in an area near the ROI, was then subtracted from the ROI intensity to obtain the integrated density value 
(IDV). The same ROI dimensions were used for all bands in all experiments. The IDV of the bands of interest 
were normalized to their corresponding βactin bands, and then to the control without RA in order to account for 
the variability of each independent experiment. Results are representative of at least 2 independent experiments.
Immunolabelling of neuron differentiation markers, Smad, GSK3β and Akt. SH-SY5Y cells 
grown to 80% confluence on sterile microscope coverslips were washed with PBS and incubated with equimolar 
concentrations (0.1 or 1 nM) of BMP-9, pBMP-9 or SpBMP-9 with and without 10 µM RA for 5d for neuron dif-
ferentiation markers and with 0.1 nM BMP-9, pBMP-9 or SpBMP-9 +/− 10 μM RA for 2 h (Akt) or 4 h (GSK3β). 
Treated cells were fixed by immersion in 3% (w/v) paraformaldehyde (Sigma) for 15 min at room temperature 
and permeabilized by immersion in 0.5% (v/v) Triton X-100 (Sigma) for 5 min. Non-specific sites were blocked by 
incubation with 1–3% (m/v) bovine serum albumin at 37 °C for 30 min. The coverslips/cells were then incubated 
at 37 °C for 30 min with primary antibodies: phosphorylated Smad1/5: anti-phospho-Smad 1/5 (Ser463/465) 
(41D10) rabbit mAb diluted 1:50 (Cell Signalling, MA, USA), βIII-tubulin: anti- βIII-tubulin IgG clone 
AA2 + AlexaFluor 488 conjugated diluted 1:250 (EMD Millipore, Etobicoke, ON, CA), microtubule-associated 
protein 2 (MAP-2): anti-MAP2 monoclonal IgG clone AP20 diluted 1:120 (EMD Millipore, Etobicoke, ON, 
CA), neuron-specific antigen (NeuN): anti-NeuN monoclonal IgG diluted 1:50 (EMD Millipore, Etobicoke, ON, 
CA), NSE: anti-NSE monoclonal IgG clone 5E2 diluted 1:200 (EMD Millipore, Etobicoke, ON, CA), ChAT: goat 
anti-ChAT IgG diluted 1:100 (EMD Millipore, Etobicoke, ON, CA), VAchT: anti-VAchT polyclonal IgG diluted 
1:100 (EMD Millipore, Etobicoke, ON, CA), Anti-phosphorylated Akt (Thr308) diluted 1:100 (Cell Signalling, 
MA, USA) or anti-phosphorylated GSK3β (Ser9) diluted 1:100 (Cell Signalling, MA, USA). The coverslips/cells 
were then washed with PBS and incubated (37 °C for 30 min) with secondary antibodies: anti-mouse polyclonal 
IgG conjugated to AlexaFluor 488 diluted 1:400 (Life Technologies, Carlsbad, CA, USA), anti-rabbit polyclonal 
IgG conjugated to FITC diluted 1:100 (Sigma), anti-rabbit polyclonal IgG conjugated to Cy3 diluted 1:100 (Sigma) 
or anti-goat polyclonal IgG conjugated to FITC diluted 1:200 (Sigma). Cell nuclei and actin cytoskeleton were 
counterstained with Hoechst 33342 (5 µg/mL) (Life Technologies, Carlsbad, CA, USA) and phalloidin-Alexa 594 
diluted 1:100 (Life Technologies, Carlsbad, CA, USA) respectively. The coverslips/cell were mounted on micro-
scope slides with 1:1 PBS-glycerol solution and at least 10 fluorescence pictures for each color filter per replicate 
were randomly taken using an Evos FL auto fluorescence microscope (Life Technologies, Carlsbad, CA, USA); 
magnification: 10X and 40X. Results are representative of at least 2 independent experiments. For each color 
channel, the same exposure time, digital gain and light intensity were used.
Measurement of immunofluorescence relative intensity. Immunofluorescence relative intensity 
quantification was assessed using a pixel-wise image analysis app (Matlab Image Processing Toolbox; MatLab 
2007b, Mathworks, USA). Briefly, the relative fluorescence intensity (RFI) corresponding to the marker of interest 
in each picture was calculated as the cumulative sum of the value of each pixel above a pre-determined threshold. 
The cumulative sum of the given marker of interest of each image was then normalized in respect to the RFI of 
the staining corresponding to the nucleus following the same procedure. Since the pictures of every independent 
experiment had the same fluorescent light intensity, acquisition time and exposure for each channel, experimen-
tal condition could be compared together. At least 5 to 10 pictures with a magnification of 40X were analyzed 
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per independent experiment for each experimental condition and at least 2 independent experiments were per-
formed. The overall RFU mean (RFI of marker of interest/RFI of the nuclei) was determined as a weighted mean 
relative to the inverse of the variance of each independent experiment.
Intracellular acetylcholine and acetylcholinesterase assay. SH-SY5Y cells were grown to 80% con-
fluence on 60-mm petri dishes, washed with sterile PBS and incubated for 3d and 5d with equimolar concen-
trations (0, 0.1 or 1 nM) of BMP-9, pBMP-9 or SpBMP-9 in serum-free medium with or without 10 µM RA. 
Incubated cells were washed with cold sterile PBS and lysed at 4 °C with 50 mM Tris-HCl (pH 7.4) contain-
ing complete mini-protease inhibitor cocktail (Roche Diagnostics, Indianapolis, IN, USA). Supernatants were 
collected and protein concentrations, OD at 280 nm, were measured with Biotek Synergy HT with a Take3 
micro-volume plate adaptor and Gene5 data analysis software (Biotek® Instruments Inc., Winosski, VT, USA). 
Acetylcholine (Ach) concentration and acetylcholinesterase (AchE) activities were assayed by fluorescence detec-
tion using Amplex® Red Acetylcholine/Acetylcholinesterase Assay Kit (Life Technologies, Carlsbad, CA, USA) 
following the manufacturer’s instructions. Briefly, Ach was measured by mixing samples with choline oxidase, 
horseradish peroxidase, Amplex Red® reagent and excess AchE; AchE activity was measured with excess Ach. 
AchE catalyzes the hydrolysis of Ach to acetate and choline, and choline oxidase then breaks down the choline 
into betaine aldehyde and oxygen peroxide. The resulting oxygen peroxide is reduced by horseradish peroxidase 
and this reacts with Amplex Red® to give a fluorochrome. The fluorescence, measured with a spectrophotometer 
(Safire2, Tecan US inc., NC, USA), is a measure of the AchE activity. The Ach concentrations and AchE activities 
were normalized to the protein content and then to their respective controls. At least four independent experi-
ments were performed.
Statistical analysis. Statistical analyses were performed with Excel (Excel 2010®). Analyses of variance 
(ANOVA) used confidence limits of 95% followed by a Tukey post-hoc test to determined significant differences 
within treatments. Only differences with a p < 0.05 were considered significant.
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